NCT05198804 2026-03-18
A Study of Azenosertib (ZN-c3) and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Phase 1/2 Completed
Clinical Trials
21 trialsNCT06412120 2026-03-16
Study Evaluating Safety, Tolerability, and Metabolism of Niraparib
University of Miami
Phase 4 Recruiting
NCT03586661 2026-03-11
Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT02655016 2026-03-10
A Study of Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy
Tesaro, Inc.
Phase 3 Active not recruiting
NCT06915025 2026-02-27
OVATION-3
Imunon
Phase 3 Recruiting
NCT06433219 2026-02-18
Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)
EMD Serono
Phase 2 Active not recruiting
NCT03602859 2025-12-31
FIRST
Tesaro, Inc.
Phase 3 Active not recruiting
NCT05021562 2025-12-31
A Study of Niraparib in Patients With Ovarian Cancer in Clinical Practice
Takeda
Active not recruiting
NCT06180356 2025-11-28
ANALLISA
MedSIR
Phase 2 Recruiting
NCT06964165 2025-11-26
A Study Comparing Niraparib Versus Platinum-Taxane Doublet Chemotherapy as Neoadjuvant Treatment in Participants With Homologous Recombination-Deficient Stage III/IV Ovarian Cancer (COHORT-C)
Tesaro, Inc.
Phase 2 Terminated
NCT04641247 2025-09-29
A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study
GlaxoSmithKline
Phase 2 Recruiting
NCT05009082 2025-09-10
Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy in Advanced Ovarian Cancer
AGO Study Group
Phase 3 Recruiting
NCT03326193 2025-07-31
A Study of Niraparib Combined With Bevacizumab Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy
Tesaro, Inc.
Phase 2 Completed
NCT03574779 2025-07-15
OPAL
Tesaro, Inc.
Phase 2 Completed
NCT05335993 2025-07-10
A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.
CanariaBio Inc.
Phase 2 Active not recruiting
NCT03783949 2025-06-11
EUDARIO
Universitaire Ziekenhuizen KU Leuven
Phase 2 Completed
NCT05672095 2025-05-23
Niraparib and Selenium for the Treatment of Recurrent BRCA Negative Platinum Resistant Ovarian Cancer
City of Hope Medical Center
Phase 1/2 Withdrawn
NCT04502602 2025-05-04
iNNOVATE
Virginia Commonwealth University
Phase 1 Active not recruiting
NCT05990192 2025-04-22
SOPRANO
Institute of Cancer Research, United Kingdom
Phase 2 Recruiting
NCT05523440 2025-03-28
Bevacizumab and/or Niraparib in Patients With Recurrent Endometrial and/or Ovarian Cancer With ARID1A Mutation
University of Oklahoma
Phase 2 Terminated
NCT06887933 2025-03-21
A Trial to Evaluate the Safety of Niraparib Tablets in Adult Female Participants With Advanced or Relapsed Epithelial Ovarian Cancer
GlaxoSmithKline
Phase 4 Not yet recruiting